SRPT Q3 2023 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$332M+44.1% YoY

Gross Profit

$295M88.8% margin

Operating Income

-$21M-6.3% margin

Net Income

-$41M-12.3% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+27.0%

Cash Flow

Operating Cash Flow

-$115M

Free Cash Flow

-$155M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.3B

Stockholders' Equity

$764M

Cash & Equivalents

$542M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$332M	$230M	+44.1%
Gross Profit	$295M	$190M	+54.9%
Operating Income	-$21M	-$131M	+84.1%
Net Income	-$41M	-$258M	+84.1%

Geographic Segments

UNITED STATES

$198M82%

Rest of World

$42M18%